TARS
Tarsus Pharmaceuticals, Inc. NASDAQ Listed Oct 16, 2020$63.96
Mkt Cap $2.7B
52w Low $38.51
54.5% of range
52w High $85.25
50d MA $68.60
200d MA $66.45
P/E (TTM)
-40.0x
EV/EBITDA
-62.1x
P/B
7.7x
Debt/Equity
0.3x
ROE
-19.3%
P/FCF
-153.4x
RSI (14)
—
ATR (14)
—
Beta
0.63
50d MA
$68.60
200d MA
$66.45
Avg Volume
570.6K
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
15440 Laguna Canyon Road · Irvine, CA 92618 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.40 | -0.16 | +60.0% | 64.76 | -3.2% | -1.2% | — | — | — | — | — |
| Feb 23, 2026 | AMC | -0.10 | -0.20 | -94.2% | 69.59 | +7.1% | +7.8% | -3.1% | +4.4% | -0.5% | +2.5% | — |
| Nov 4, 2025 | AMC | -0.35 | -0.30 | +14.3% | 71.50 | -4.2% | -4.6% | -0.2% | +0.2% | +6.7% | +3.9% | — |
| Aug 6, 2025 | AMC | -0.33 | -0.48 | -45.5% | 41.64 | +8.0% | +15.2% | -0.2% | +4.6% | +2.6% | +2.6% | — |
| May 1, 2025 | AMC | -0.69 | -0.64 | +7.2% | 50.30 | -2.8% | -5.8% | +1.4% | -3.2% | +1.9% | -0.4% | — |
| Feb 25, 2025 | AMC | -0.68 | -0.60 | +11.8% | 41.29 | +2.6% | +3.1% | +2.3% | +2.1% | -4.0% | +4.2% | — |
| Nov 13, 2024 | AMC | -0.94 | -0.61 | +35.1% | 46.51 | +9.7% | +0.3% | -3.9% | -0.4% | +5.1% | -0.7% | — |
| Aug 8, 2024 | AMC | -0.98 | -0.88 | +10.2% | 23.61 | +14.4% | +13.7% | -2.4% | +0.9% | +0.8% | +1.1% | — |
| May 8, 2024 | AMC | -1.15 | -1.01 | +12.2% | 37.35 | +13.8% | -8.9% | +8.7% | +3.7% | -1.0% | +1.3% | — |
| Feb 27, 2024 | AMC | -1.37 | -1.31 | +4.4% | 39.22 | +3.0% | -3.4% | +0.9% | -3.3% | -0.2% | -3.0% | — |
| Nov 9, 2023 | AMC | -1.40 | -1.28 | +8.6% | 15.57 | +9.6% | +12.2% | -1.7% | +4.4% | +0.1% | -1.1% | — |
| Aug 10, 2023 | AMC | -1.08 | -1.17 | -8.3% | 17.01 | -1.7% | -1.1% | +0.1% | +1.0% | -1.4% | -1.7% | — |
| May 9, 2023 | AMC | -0.95 | -0.88 | +7.4% | 16.09 | +2.5% | +3.8% | +2.2% | -3.3% | +0.4% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Oppenheimer | Reiterates | Outperform | $98 | $60.97 | $61.07 | +0.2% | +0.8% | -0.8% | +1.9% | -2.3% | +4.8% |
| Feb 25 | Guggenheim | Maintains | Buy → Buy | — | $75.01 | $74.97 | -0.1% | -3.1% | +4.4% | -0.5% | +2.5% | -1.1% |
| Feb 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $75.01 | $74.97 | -0.1% | -3.1% | +4.4% | -0.5% | +2.5% | -1.1% |
| Nov 5 | Guggenheim | Maintains | Buy → Buy | — | $71.50 | $68.50 | -4.2% | -4.6% | -0.2% | +0.2% | +6.7% | +3.9% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $72.93 | $73.99 | +1.5% | -2.4% | -0.5% | -3.0% | -0.6% | -3.3% |
| May 5 | Goldman Sachs | Maintains | Neutral → Neutral | — | $47.36 | $46.95 | -0.9% | +1.4% | -3.2% | +1.9% | -0.4% | -5.0% |
| May 2 | Guggenheim | Maintains | Buy → Buy | — | $50.30 | $48.89 | -2.8% | -5.8% | +1.4% | -3.2% | +1.9% | -0.4% |
| Mar 6 | Jefferies | Maintains | Buy → Buy | — | $44.54 | $43.80 | -1.7% | -2.2% | +6.7% | -4.0% | +5.7% | -0.1% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.29 | $42.35 | +2.6% | +3.1% | +2.3% | +2.1% | -4.0% | +4.2% |
| Feb 26 | Guggenheim | Maintains | Buy → Buy | — | $41.29 | $42.35 | +2.6% | +3.1% | +2.3% | +2.1% | -4.0% | +4.2% |
| Feb 26 | Barclays | Maintains | Overweight → Overweight | — | $41.29 | $42.35 | +2.6% | +3.1% | +2.3% | +2.1% | -4.0% | +4.2% |
| Feb 24 | Guggenheim | Maintains | Buy → Buy | — | $47.84 | $48.20 | +0.8% | -4.8% | -9.3% | +3.1% | +2.3% | +2.1% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $52.95 | $53.33 | +0.7% | -2.2% | -1.0% | +2.2% | -0.2% | -3.8% |
| Jan 27 | Barclays | Maintains | Overweight → Overweight | — | $48.78 | $48.69 | -0.2% | +5.5% | -0.8% | +3.9% | -2.5% | +3.9% |
| Jan 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $46.74 | $46.73 | -0.0% | +2.9% | +2.1% | -0.7% | +5.5% | -0.8% |
| Nov 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $46.65 | $46.50 | -0.3% | -3.9% | -0.4% | +5.1% | -0.7% | -0.4% |
| Nov 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $46.51 | $51.00 | +9.7% | +0.3% | -3.9% | -0.4% | +5.1% | -0.7% |
| Aug 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $23.61 | $27.00 | +14.4% | +13.7% | -2.4% | +0.9% | +0.8% | +1.1% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.00 | $37.00 | +0.0% | +3.7% | -1.0% | +1.3% | +0.2% | -0.9% |
| May 10 | Barclays | Maintains | Overweight → Overweight | — | $34.04 | $34.36 | +0.9% | +8.7% | +3.7% | -1.0% | +1.3% | +0.2% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $37.35 | $42.50 | +13.8% | -8.9% | +8.7% | +3.7% | -1.0% | +1.3% |
| Mar 6 | Jefferies | Maintains | Buy → Buy | — | $35.77 | $36.38 | +1.7% | +1.9% | -2.6% | -6.1% | -8.5% | +0.4% |
| Feb 29 | Goldman Sachs | Maintains | Neutral → Neutral | — | $37.87 | $38.89 | +2.7% | +0.9% | -3.3% | -0.2% | -3.0% | +1.9% |
| Feb 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $39.22 | $40.40 | +3.0% | -3.4% | +0.9% | -3.3% | -0.2% | -3.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.22 | $40.40 | +3.0% | -3.4% | +0.9% | -3.3% | -0.2% | -3.0% |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | $39.22 | $40.40 | +3.0% | -3.4% | +0.9% | -3.3% | -0.2% | -3.0% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.57 | $17.07 | +9.6% | +12.2% | -1.7% | +4.4% | +0.1% | -1.1% |
| Sep 11 | Guggenheim | Maintains | Buy → Buy | — | $16.05 | $16.47 | +2.6% | +5.8% | -3.2% | -8.8% | -1.6% | +9.4% |
| Aug 14 | Guggenheim | Maintains | Buy → Buy | — | $16.82 | $16.73 | -0.5% | +0.1% | +1.0% | -1.4% | -1.7% | +3.9% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.01 | $16.72 | -1.7% | -1.1% | +0.1% | +1.0% | -1.4% | -1.7% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.04 | $18.83 | +4.4% | +10.2% | +15.7% | -0.3% | -3.9% | -17.0% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.25 | $18.45 | +1.1% | -6.0% | -0.8% | +5.1% | -0.5% | +1.6% |
| Jun 16 | Guggenheim | Maintains | Buy → Buy | — | $18.62 | $18.86 | +1.3% | -0.6% | +3.0% | -3.7% | -2.0% | +1.4% |
| May 18 | Guggenheim | Maintains | Buy → Buy | — | $15.93 | $16.31 | +2.4% | +1.3% | +0.2% | +0.5% | +1.6% | -2.4% |
| May 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.35 | $15.35 | +0.0% | +1.6% | +3.2% | +3.8% | +2.2% | -3.3% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.31 | $14.06 | -1.7% | -4.0% | -2.3% | -5.0% | +2.4% | -1.1% |
| Aug 1 | Barclays | Maintains | Overweight → Overweight | — | $15.02 | $15.95 | +6.2% | +1.9% | +8.8% | +3.2% | -0.2% | -0.3% |
| Dec 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.13 | $24.87 | +3.1% | +11.4% | -4.2% | +0.7% | -1.6% | -3.6% |
| Nov 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $25.25 | $26.42 | +4.6% | +7.7% | +1.8% | -9.7% | +10.3% | -3.6% |
| Oct 8 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $22.12 | $23.59 | +6.6% | +11.1% | -1.5% | +10.8% | +10.7% | -5.3% |
| Jun 29 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $28.49 | $29.53 | +3.7% | +5.4% | -3.5% | +0.1% | -1.2% | +0.4% |
| Nov 10 | Jefferies | Maintains | Buy → Buy | — | $23.19 | $23.90 | +3.1% | -8.6% | +1.0% | +3.9% | +10.2% | +2.0% |
| Nov 10 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $23.19 | $23.90 | +3.1% | -8.6% | +1.0% | +3.9% | +10.2% | +2.0% |
| Nov 10 | BofA Securities | Maintains | Buy → Buy | — | $23.19 | $23.90 | +3.1% | -8.6% | +1.0% | +3.9% | +10.2% | +2.0% |
| Nov 10 | Raymond James | Downgrade | Strong Buy → Buy | — | $23.19 | $23.90 | +3.1% | -8.6% | +1.0% | +3.9% | +10.2% | +2.0% |
No insider trades available.
8-K
Tarsus Pharmaceuticals, Inc. -- 8-K Filing
Tarsus Pharmaceuticals nearly tripled XDEMVY sales to $451.4 million in 2025, projects over $2 billion peak sales potential, and advances pipeline candidates TP-04 and TP-05 into Phase 2 trials.
Feb 23
8-K · 5.02
!!! Very High
Tarsus Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Tarsus Pharmaceuticals appointed David E.I. Pyott as a Class III director, adding experienced leadership to its board governance.
Feb 18
Data updated apr 27, 2026 3:59am
· Source: massive.com